A method for preparing drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine

Through multi-step reaction, 2-hydrazine pyridine was combined with bromination agent and ammonization reagent, and 1,2,4-triazolo[4,3-A]pyridine-3-amine was successfully prepared, and cyano bromide was solved The toxicity problem in industrial applications has achieved an efficient and environmentally friendly preparation method and is suitable for industrial production.

CN116217571BActive Publication Date: 2024-11-15SHANGHAI RUIPU PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310316557.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-28
Publication Date
2024-11-15
Estimated Expiration
2043-03-28

AI Technical Summary

Technical Problem

The existing preparation of 1,2,4-triazolo[4,3-A]pyridine-3-amine uses highly toxic cyano bromide, which limits its use in industrial applications and requires the development of new green environmental protection. Preparation method.

Method used

2-hydrazine pyridine reacts with cyclization reagent to produce [1,2,4]triazolo[4,3-A]pyridine, and then reacts with bromination agent and ammonization reagent, and 1,2 are obtained by synthesis through multiple steps. ,4-triazolo[4,3-A]pyridine-3-amine, use easy-to-get raw materials, avoid the use of dangerous reagents, and use suitable solvents and reaction conditions.

Benefits of technology

The preparation of 1,2,4-triazolo[4,3-A]pyridine-3-amine with high yield and high purity is achieved. It is suitable for industrial production, and is not highly toxic to use, and is green and environmentally friendly.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116217571B_ABST
    Figure CN116217571B_ABST
Patent Text Reader

Abstract

The invention discloses a method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, and belongs to the field of organic chemical synthesis. The method comprises the following specific steps: step 1: dissolving 2-hydrazine pyridine in a solvent, and dropping a cyclization reagent to generate a [1,2,4]triazolo[4,3-A]pyridine as shown in formula (I); step 2: dissolving [1,2,4]triazolo[4,3-A]pyridine in a solvent, and then reacting with a brominating agent to generate a compound 3-bromo-[1,2,4]thiazolo[4,3-A]pyridine as shown in formula (II); and step 3: dissolving 3-bromo-[1,2,4]thiazolo[4,3-A]pyridine in a solvent, and then reacting with an aminating agent to generate a compound 1,2,4-triazolo[4,3-A]pyridine-3-amine as shown in formula (III). The synthesis of the invention uses readily available raw materials, is simple to operate, uses no hazardous reagents, is green and environmentally friendly, and has high product yield and purity, which is conducive to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of organic chemical synthesis, and in particular to a method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine. Background Art

[0002] Nitrogen heterocycles are one of the most important structural components of drugs. Nitrogen heterocycles are commonly found in natural products such as nucleosides, amino acids, sugars, vitamins, and alkaloids, and are often used by medicinal chemists to design small molecule drugs. The introduction of heterocyclic structures into drug molecules has a great effect on improving drug selectivity and utilization, lipid solubility and water solubility, and molecular polarity. From 2015 to the present, more than 75% of the small molecule drugs approved by the US Food and Drug Administration contain nitrogen heterocycle molecules.

[0003] 1,2,4-Triazolo[4,3-A]pyridine-3-amine is a member of the family of drug building blocks containing nitrogen heterocyclic molecules. Bristol-Myers Squibb Company of the United States reported in its patent (JP5714745) that small molecule drugs containing the fragment of 1,2,4-triazolo[4,3-A]pyridine-3-amine can be used to treat diseases such as schizophrenia and neurological degeneration. In this patent (JP5714745) and the literature (Journal of Heterocyclic Chemistry, 2003, vol.40, 1, p.191-19), the preparation route of 1,2,4-triazolo[4,3-A]pyridine-3-amine is reported as follows:

[0004]

[0005] This method uses di(1-hydrogen-imidazolyl)imine, which is synthesized from imidazole and cyanogen bromide as follows:

[0006]

[0007] In addition, some documents such as Journal of Organic Chemistry, 1966, vol. 31, p. 251-260, Zeitschrift fur Naturforschung, 1959, vol. 14b, p. 601 also reported the use of 2-hydrazinepyridine and cyanogen bromide to synthesize 1,2,4-triazolo[4,3-A]pyridine-3-amine. However, cyanogen bromide is a highly toxic product and will decompose into highly toxic hydrogen cyanide, which is greatly limited in industrial application.

[0008] Due to the limitations of cyanogen bromide in industrial applications, the current method for preparing 1,2,4-triazolo[4,3-A]pyridine-3-amine is not suitable for industrial production, and it is necessary to develop a new method for preparing 1,2,4-triazolo[4,3-A]pyridine-3-amine. Summary of the invention

[0009] The present invention aims to provide a novel method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine to solve the problems raised in the above background technology.

[0010] The method for preparing the drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine adopts the following synthetic route:

[0011]

[0012] The specific steps include:

[0013] Step 1: dissolving 2-hydrazinepyridine in a solvent, and adding a cyclization reagent dropwise to generate [1,2,4]triazolo[4,3-A]pyridine as shown in formula (I);

[0014] Step 2: dissolving [1,2,4]triazolo[4,3-A]pyridine in a solvent, and then reacting with a brominating agent to generate a compound 3-bromo-[1,2,4]thiazolo[4,3-A]pyridine as shown in formula (II);

[0015] Step 3: Dissolve 3-bromo-[1,2,4]thiazolo[4,3-A]pyridine in a solvent, and then react with an aminating agent to generate a compound 1,2,4-triazolo[4,3-A]pyridine-3-amine as shown in formula (III).

[0016] As a further solution of the present invention: in step 1, the solvent can be selected from one of formic acid, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, dichloromethane, petroleum ether, ethyl acetate, etc., preferably formic acid.

[0017] As a further solution of the present invention: in step 1, the reaction temperature is 50-180° C., preferably 100-150° C., and the reaction time is 3-24 h, preferably 8 h.

[0018] As a further solution of the present invention: in step 1, the cyclization reagent can be selected from one of trimethyl orthoformate, triethyl orthoformate, etc., preferably triethyl orthoformate.

[0019] As a further scheme of the present invention: in step 1, the molar ratio of 2-hydrazinepyridine to the cyclization reagent is 1:(1-50), preferably 1:3, and the volume ratio of 2-hydrazinepyridine to the solvent is 1:(1-30), preferably 1:5.

[0020] As a further solution of the present invention: in step 2, the solvent can be selected from one of dichloromethane, dichloroethane, chloroform, N,N-dimethylformamide, tetrahydrofuran, 2-methyltetrahydrofuran, etc., preferably dichloromethane.

[0021] As a further scheme of the present invention: in step 2, the bromination reagent can be selected from one of 1,3-dibromo-5,5-dimethylhydantoin, N-bromosuccinimide, dibromohydantoin, 4-carbon tetrabromide, bromine, pyridinium tribromide, etc., preferably N-bromosuccinimide.

[0022] As a further solution of the present invention: in step 2, the reaction temperature is 10-100° C., preferably 20-50° C., and the reaction time is 2-24 hours, preferably 5 hours.

[0023] As a further scheme of the present invention: in step 2, the molar ratio of compound I to the bromination reagent is 1:(1-10), preferably 1:2, and the volume ratio of compound I to the solvent is 1:(1-20), preferably 1:6.

[0024] As a further solution of the present invention: in step three, the solvent can be selected from one of toluene, xylene, N-methylpyrrolidone, N,N-dimethylformamide, N,N-dimethylacetamide, water, etc., preferably N,N-dimethylformamide.

[0025] As a further solution of the present invention: in step 3, the aminating agent can be selected from one of aqueous ammonia, hydroxylamine-O-sulfonic acid, hydroxylamine hydrochloride, hydroxylamine sulfate, N,O-dimethylhydroxylamine hydrochloride, diethyl aminophosphorate, etc., preferably aqueous ammonia.

[0026] As a further solution of the present invention: in step 3, the reaction temperature is 20-200° C., preferably 100-150° C., and the reaction time is 5-24 hours, preferably 8 hours.

[0027] As a further scheme of the present invention: in step 3, the molar ratio of compound II to the aminating agent is 1:(1-20), preferably 1:3, and the volume ratio of compound II to the solvent is 1:(1-25), preferably 1:5.

[0028] The beneficial effects of the present invention are: the raw materials are easily available, the operation is simple, no dangerous reagents are used, it is green and environmentally friendly, and the product has high yield and high purity, which is conducive to industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the nuclear magnetic resonance spectrum of the drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine prepared in Example 1 of the present invention. DETAILED DESCRIPTION

[0030] In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail by enumerating examples below. It should be noted that the specific implementation described here is only used to explain the present invention and is not used to limit the present invention.

[0031] In the following examples, unless otherwise specified, all raw materials are commercially available or prepared by conventional methods in the art. The method for preparing the drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine adopts the following synthetic route:

[0032]

[0033] Example 1

[0034] Step 1: Add 2-hydrazinepyridine (100 g), triethyl orthoformate (500 ml) and formic acid (500 ml) into a reaction bottle, turn on magnetic stirring, react at 140°C for 8 h, then concentrate the reaction solution to half the volume, filter out solid precipitation, and put the filter cake into an oven at 60°C to dry, to obtain 107.0 g of compound I, with a yield of 98%.

[0035] Step 2: Compound I (100 g), N-bromosuccinimide (291 g), and dichloromethane (600 ml) were put into a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 25° C. for 5 h. Then 500 ml of water was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted twice with dichloromethane. The organic layer was collected, washed with saturated sodium chloride, and then 20 g of anhydrous sodium sulfate was added to dry the organic layer. The organic layer was filtered and the organic layer was spin-dried to obtain 161.2 g of compound II with a yield of 97%.

[0036] Step 3: Compound II (100 g), concentrated ammonia (400 ml), and N,N-dimethylformamide (500 ml) were added to a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 120°C for 8 h. Then 1000 ml of water was added to the reaction solution, the water layer was extracted three times with 500 ml of ethyl acetate, and then the organic layer was washed with 1000 ml of saturated sodium chloride aqueous solution, the organic layer was separated, and the ethyl acetate layer was dried with 100 g of anhydrous sodium sulfate, filtered, and the ethyl acetate layer was spin-dried to obtain 62.3 g of light yellow drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, with a yield of 92%. 1 H NMR (400MHz, DMSO-d6) δ 8.05 (d, J = 7.0 Hz, 1H), 7.43 (d, J = 9.4 Hz, 1H), 7.06 (dd, J = 9.5, 6.4 Hz, 1H), 6.73 (t, J = 6.7 Hz, 1H), 6.41 (s, 2H).

[0037] The compound III prepared in Example 1 was subjected to NMR analysis, and the NMR spectrum of the drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine was as follows: Figure 1 shown.

[0038] Example 2

[0039] Step 1: Add 2-hydrazinepyridine (100 g), triethyl orthoformate (500 ml) and formic acid (1000 ml) into a reaction bottle, turn on magnetic stirring, react at 150°C for 24 hours, then concentrate the reaction solution to half the volume, filter out solid precipitation, and put the filter cake into an oven at 60°C to dry, to obtain 104.8 g of compound I, with a yield of 96%.

[0040] Step 2: Compound I (100 g), dibromohydantoin (291 g), and dichloromethane (1000 ml) were placed in a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 25° C. for 24 h. Then 1000 ml of water was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted twice with dichloromethane. The organic layer was collected, washed with saturated sodium chloride, and then 20 g of anhydrous sodium sulfate was added to dry the organic layer. The organic layer was filtered and the organic layer was spin-dried to obtain 157.9 g of compound II with a yield of 95%.

[0041] Step 3: Compound II (100 g), hydroxylamine hydrochloride (105 g), and N,N-dimethylacetamide (1000 ml) were placed in a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 150° C. for 24 h. Then 2000 ml of water was added to the reaction solution, the water layer was extracted three times with 500 ml of ethyl acetate, and then the organic layer was washed with 1000 ml of saturated sodium chloride aqueous solution, the organic layer was separated, and the ethyl acetate layer was dried with 100 g of anhydrous sodium sulfate, filtered, and the ethyl acetate layer was spin-dried to obtain 60.9 g of light yellow drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, with a yield of 90%.

[0042] Example 3

[0043] Step 1: 2-Hydrazopyridine (100 g), trimethyl orthoformate (1000 ml) and formic acid (500 ml) were put into a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 140° C. for 8 h. The reaction solution was then concentrated to half the volume. Solids precipitated and filtered. The filter cake was placed in an oven and dried at 60° C. to obtain 105.9 g of compound I with a yield of 97%.

[0044] Step 2: Compound I (100 g), 1,3-dibromo-5,5-dimethylhydantoin (582 g), and dichloromethane (600 ml) were put into a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 25° C. for 5 h. Then 500 ml of water was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted twice with dichloromethane. The organic layer was collected, washed with saturated sodium chloride, and then 20 g of anhydrous sodium sulfate was added to dry the organic layer, filtered, and finally the organic layer was spin-dried to obtain 159.6 g of compound II with a yield of 96%.

[0045] Step 3: Compound II (100 g), concentrated ammonia (103 ml), and N-methylpyrrolidone (500 ml) were placed in a reaction flask, magnetic stirring was turned on, and the mixture was reacted at 120° C. for 8 h. Then 1000 ml of water was added to the reaction solution, the aqueous layer was extracted three times with 500 ml of ethyl acetate, and then the organic layer was washed with 1000 ml of saturated sodium chloride aqueous solution, the organic layer was separated, the ethyl acetate layer was dried with 100 g of anhydrous sodium sulfate, filtered, and the ethyl acetate layer was spin-dried to obtain 61.6 g of light yellow drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, with a yield of 91%.

[0046] Example 4

[0047] Step 1: Add 2-hydrazinepyridine (20 g), triethyl orthoformate (30 ml) and formic acid (20 ml) into a reaction bottle, turn on magnetic stirring, react at 50°C for 3 h, then concentrate the reaction solution to half the volume, filter out solid precipitation, and put the filter cake into an oven at 60°C to dry, to obtain 20.3 g of compound I, with a yield of 93%.

[0048] Step 2: Compound I (20 g), N-bromosuccinimide (30 g), and dichloroethane (20 ml) were put into a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 50° C. for 24 h. Then 30 ml of water was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted twice with dichloromethane. The organic layer was collected, washed with saturated sodium chloride, and then 2 g of anhydrous sodium sulfate was added to dry the organic layer, filtered, and finally the organic layer was spin-dried to obtain 30.9 g of compound II with a yield of 93%.

[0049] Step 3: Compound II (20 g), concentrated ammonia (6.7 ml), and N,N-dimethylformamide (20 ml) were added to a reaction bottle, magnetic stirring was turned on, and the mixture was reacted at 120°C for 8 h. Then 40 ml of water was added to the reaction solution, the aqueous layer was extracted three times with 20 ml of ethyl acetate, and then the organic layer was washed with 10 ml of saturated sodium chloride aqueous solution, the organic layer was separated, the ethyl acetate layer was dried with 1 g of anhydrous sodium sulfate, filtered, and the ethyl acetate layer was spin-dried to obtain 12.5 g of a light yellow drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, with a yield of 92%.

[0050] Example 5

[0051] Step 1: 2-Hydrazopyridine (10 g), triethyl orthoformate (780 ml) and toluene (300 ml) were placed in a reaction bottle, magnetic stirring was turned on, and the reaction was carried out at 140°C for 8 h. The reaction solution was then concentrated to half the volume. Solid precipitated and filtered. The filter cake was placed in an oven at 60°C and dried to obtain 10.3 g of compound I with a yield of 94%.

[0052] Step 2: Compound I (10 g), N-bromosuccinimide (150 g), and dichloromethane (200 ml) were placed in a reaction flask, magnetic stirring was turned on, and the reaction was carried out at 25° C. for 5 h. Then 300 ml of water was added to the reaction solution, the organic layer was separated, and the aqueous layer was extracted twice with dichloromethane. The organic layer was collected, washed with saturated sodium chloride, and then 2 g of anhydrous sodium sulfate was added to dry the organic layer. The organic layer was filtered and the organic layer was spin-dried to obtain 15.5 g of compound II with a yield of 93%.

[0053] Step 3: Compound II (10 g), concentrated ammonia (67.5 ml), and toluene (250 ml) were placed in a reaction flask, magnetic stirring was turned on, and the reaction was carried out at 100° C. for 8 h. Then 500 ml of water was added to the reaction solution, the water layer was extracted three times with 200 ml of ethyl acetate, and then the organic layer was washed with 200 ml of saturated sodium chloride aqueous solution, the organic layer was separated, the ethyl acetate layer was dried with 20 g of anhydrous sodium sulfate, filtered, and the ethyl acetate layer was spin-dried to obtain 6.3 g of light yellow drug building block 1,2,4-triazolo[4,3-A]pyridine-3-amine, with a yield of 93%.

[0054] The above description is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several improvements without departing from the principle of the present invention, and these improvements should also be regarded as within the protection scope of the present invention.

Claims

1. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine, characterized in that: The synthetic route is: The specific steps of the route are: Step 1, dissolving 2-hydrazinepyridine in a solvent, and adding a cyclization reagent dropwise to generate a compound [1,2,4]triazolo[4,3-A]pyridine represented by formula (I); the reaction parameters for preparing formula (I) in step 1 are: temperature of 50 to 180° C., and time of 3 to 24 hours; Step 2, dissolving the compound (I) prepared in step 1 in a solvent, and then reacting with a brominating agent to generate a compound 3-bromo-[1,2,4]triazolo[4,3-A]pyridine as shown in formula (II); the reaction parameters for preparing the compound (II) in step 2 are: temperature of 10 to 100° C.; time of 2 to 24 hours; Step 3, dissolving the compound (II) prepared in step 2 in a solvent, and then reacting with an aminating agent to generate a compound 1,2,4-triazolo[4,3-A]pyridine-3-amine as shown in formula (III); the reaction parameters for preparing the compound (III) in step 3 are: temperature of 100 to 150° C., and time of 5 to 24 hours; The cyclization reagent includes one of trimethyl orthoformate and triethyl orthoformate; the bromination reagent includes one of 1,3-dibromo-5,5-dimethylhydantoin, N-bromosuccinimide, dibromohydantoin, 4-carbon tetrabromide, bromine, and pyridinium tribromide; the amination reagent is selected from one of ammonia water, hydroxylamine hydrochloride, and hydroxylamine sulfate; and the solvent in step three is selected from one of toluene, xylene, N-methylpyrrolidone, N,N-dimethylformamide, and N,N-dimethylacetamide.

2. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine according to claim 1, characterized in that: The solvent in step 1 is selected from one of formic acid, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, dichloromethane, petroleum ether and ethyl acetate.

3. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine according to claim 1, characterized in that: The molar ratio of 2-hydrazinepyridine to the cyclization reagent in step 1 is 1:(1-50); the volume ratio of 2-hydrazinepyridine to the solvent is 1:(1-30).

4. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine according to claim 1, characterized in that: The solvent in step 2 is selected from one of dichloromethane, dichloroethane, chloroform, N,N-dimethylformamide, tetrahydrofuran, and 2-methyltetrahydrofuran.

5. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine according to claim 1, characterized in that: The molar ratio of the compound (I) to the bromination reagent in step 2 is 1: (1~10); the volume ratio of formula (I) to solvent is 1:(1~20).

6. A method for preparing a drug building block 1,2,4-triazolo[4,3-A]pyridin-3-amine according to claim 1, characterized in that: In the step 3, the molar ratio of the compound (II) to the aminating agent is 1: (1~20), the volume ratio of formula (II) to solvent is 1:(1~25).